II. Indications
-
Procedural Sedation and Analgesia (PSAA)
- Other agents are preferred in most cases (unpredictable)
-
Rapid Sequence Intubation (induction agent)
- Other induction agents are preferred due to the large and unpredictable Midazolam doses required for induction
- Rarely given at adequate doses (a typical adult dose for RSI is an astounding 8-10 mg)
- Consider where IV Access unavailable or other intubation agents contraindicated
- Could be considered in Status Epilepticus (although Thiopental might be preferred)
- Other induction agents are preferred due to the large and unpredictable Midazolam doses required for induction
III. Class
- Parenteral short acting Benzodiazepine
IV. Mechanism
- Sedative, Anxiolytic, and amnestic effects
- Antagonist: Flumazenil
V. Dosing: Procedural Sedation
- Indications for Midazolam
- Ideal for procedural anxiolysis rather than sedation (e.g. Lumbar Puncture, Nasogastric Tube placement)
- Other agents are preferred for moderate Procedural Sedation in most cases
- Intranasal Versed in children may allow for imaging, Intravenous Access, Laceration Repair
- Intravenous
- Age 6 months to 5 years
- Initial: 0.05 to 0.1 mg/kg IV
- Titrate: Up to 1 mg increments IV every 3 min to max of 0.6 mg/kg
- Age 6 to 12 years
- Initial: 0.025 to 0.05 mg/kg IV
- Titrate: Up to 1 mg increments IV every 3 min to max of 0.4 mg/kg
- Adults (and over age 12 years)
- Initial: 0.02 mg/kg IV (up to 1 to 2 mg)
- Titrate: 1 mg increments IV every 2 to 3 min (typically up to 5 mg in typical adult)
- Common procedural anxiolysis dose (e.g. LP, NG placement): 1 to 2 mg IV
- Age 6 months to 5 years
- Intramuscular
- Child: 0.1 to 0.15 mg/kg (up to 5 mg)
- Adult: 0.07 mg/kg (up to 5 mg in typical adult, max: 10 mg)
- Other Dosing
- Oral: 0.5 mg/kg/dose (up to 20 mg) orally
- Nasal: 0.2 to 0.5 mg/kg intranasal (1/2 in each nostril) using 5 mg/ml up to 10 mg
- Rectal 0.25 to 0.5 mg/kg/dose (up to 20 mg) per Rectum
- Commonly used in combination with Fentanyl
- When combined with Opioids (e.g. Fentanyl), use lower Midazolam dose
- Risk of Deep Sedation with cardiopulmonary depression
VI. Dosing: Status Epilepticus
- See Status Epilepticus
- Alternative agent when longer acting Benzodiazepines not available or without IV Access (e.g. Ambulance)
- IV: 0.15 mg/kg up to 4 mg (then infused IV at 1 mcg/kg/min and titrated every 5 min as needed) up to 10 mg
- IM: 0.2 mg/kg of the IV formulation up to 10 mg
- Weight 13-40 kg: 5 mg IM
- Weight >40 kg: 10 mg IM
- Rectal: 0.25 to 0.5 mg/kg
- May be delivered via tuberculin syringe (without needle) intra-rectally
- Commercial preparations are available for home use (Diastat AcuDial at $300 for 2 doses, age >2)
- Intranasal
- Dose: 0.2 to 0.4 mg/kg up to 10 mg of the IV formulation
- Typically given via syringe with MADD atomizer attached (roughly $15)
- Commercial preparations are available for home use (Nayzilam at $550 for 2 doses, age>12)
- Buccal mucosa: 0.5 mg/kg of the IV formulation
VII. Safety
- Pregnancy Category D
- Avoid in Lactation
- Wait at least 4 hours for Breast Feeding
- Schedule IV Controlled Substance
- Unpredictable at increased doses (risk of respiratory and cardiovascular depression)
- Reversal: Flumazenil 0.01 mg/kg up to 2 mg over 15 seconds
- Do not use if on longterm Benzodiazepines
VIII. Pharmacokinetics
-
General
- Duration: 1-4 hours
- Half life: 2.5 hours
- Oral
- Onset: 20 to 30 minutes
- Peak: 40 minutes
- Intramuscular
- Onset: 5 to 7 minutes (up to 10-20 minutes)
- Peak: 10 to 15 minutes
- Duration: 60-120 minutes
- Intravenous
- Onset: 2-3 minutes
- Peak: 5 to 10 minutes
- Duration: 45-60 minutes
IX. Precautions
- Monitor closely with respiratory depression
- Have Ambubag and Oxygen available when administered
- Unpredictable at increased doses (risk of respiratory and cardiovascular depression)
- Best delivered in incremental doses (e.g. 1 mg increments)
- Risk of Hypotension
- Use with caution if risks for respiratory depression
- Elderly, debilitated patients or children
- Concurrent Narcotic use
- Existing CNS depression
- Chronic lung disease
- Neuromuscular disorder
- Apnea history
- Risk of Agitation
- Elderly
- Liver disease
X. Resources
- Midazolam Injection (DailyMed)
XI. References
- Miner (2012) APLS Lecture, HCMC, Minneapolis
- Hamilton (2012) Tarascon Pharmacopeia, Jones and Bartlett, Burlington
- Rispoli (2002) Tarascon Pocket Orthopedics, Loma Linda, p. 115
- University Minnesota Childrens - Pediatric Emergency Drug Card
- Becker (2012) Anesth Prog 59:28-42 [PubMed]
- Brown (2005) Am Fam Physician 71:85-90 [PubMed]
- Singh in Blaivas (2012) Emergency Medicine - an International Perspective, p. 199-208
Images: Related links to external sites (from Bing)
Related Studies
midazolam (on 8/17/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
MIDAZOLAM HCL 2 MG/ML SYRUP | Generic | $0.65 per ml |
Ontology: Midazolam (C0026056)
Definition (NCI_NCI-GLOSS) | A drug used to treat anxiety and tension and to relax muscles. It is also being studied in the treatment of nausea and vomiting caused by some cancer treatments. It is a type of benzodiazepine. |
Definition (NCI) | A short-acting benzodiazepine derivative with an imidazole structure and with anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. |
Definition (MSH) | A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. |
Definition (CSP) | 8-chloro-6-(2-fluorophenyl)-1-methyl- 4H- imidazo(1,5a)(1,4)benzodiazepine; short acting benzodiazepine sedative with high liability for abuse; used for preanesthesia sedation (USP lists as an injectable anesthetic). |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D008874 |
SnomedCT | 26800000, 373476007 |
LNC | LP16207-0, MTHU003397 |
English | Midazolam, 4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-, 8-Chloro-6-(2-fluorophenyl)-1-Methyl- 4H- Imidazo(1,5a)(1,4)Benzodiazepine, midazolam (medication), sedatives midazolam, Midazolam [Chemical/Ingredient], MIDAZOLAM, midazolam, Midazolam (product), Midazolam (substance) |
Swedish | Midazolam |
Czech | midazolam |
Finnish | Midatsolaami |
Russian | MIDAZOLAM, МИДАЗОЛАМ |
Japanese | ミダゾラム |
Croatian | MIDAZOLAM |
Polish | Midazolam |
Spanish | midazolam (producto), midazolam (sustancia), midazolam, Midazolam |
French | Midazolam |
German | Midazolam |
Italian | Midazolam |
Portuguese | Midazolam |
Ontology: Versed (C0042553)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D008874 |
English | versed, vers, Versed |